drugset
drugset / Trial / NCT01029132

Characteristics of Treatment Responders to Galantamine

NCT01029132 ↗

Completed 66 enrolled Samsung Medical Center Janssen Korea, Ltd., Korea · collab
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To investigate the characteristics of treatment responders to galantamine.

Timeline

Start
2007-04
Primary completion
2009-10
Completion
2009-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Galantamine Small molecule 8 mg —
Subject Galantamine Small molecule 12 mg —

Indications

dementia